CD7 and lymphoma: In the past, an anti-CD7 immunotoxin linked by disulfide bonds to Ricin was not effective in a phase I clinical trial with patients with CD7+ T cell leukemia and lymphoma [124], most probably due to dose-limiting toxicities.